Prestige Consumer Healthcare (NYSE:PBH – Free Report) had its price objective trimmed by Canaccord Genuity Group from $72.00 to $70.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.
Other research analysts have also recently issued research reports about the stock. Zacks Research cut shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $67.00.
Get Our Latest Stock Report on PBH
Prestige Consumer Healthcare Stock Down 2.9%
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.07 by $0.06. The business had revenue of $336.31 million during the quarter, compared to analysts’ expectations of $329.14 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business’s quarterly revenue was up 22.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.07 EPS. Research analysts predict that Prestige Consumer Healthcare will post 4.55 EPS for the current year.
Institutional Trading of Prestige Consumer Healthcare
Several institutional investors have recently added to or reduced their stakes in PBH. Russell Investments Group Ltd. raised its position in shares of Prestige Consumer Healthcare by 29.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 66,098 shares of the company’s stock worth $3,032,000 after buying an additional 15,052 shares in the last quarter. Fifth Third Bancorp increased its stake in Prestige Consumer Healthcare by 5.6% in the 3rd quarter. Fifth Third Bancorp now owns 62,671 shares of the company’s stock valued at $2,875,000 after buying an additional 3,341 shares during the period. King Luther Capital Management Corp lifted its holdings in shares of Prestige Consumer Healthcare by 1.2% during the 3rd quarter. King Luther Capital Management Corp now owns 92,200 shares of the company’s stock valued at $4,229,000 after buying an additional 1,122 shares during the last quarter. Maryland State Retirement & Pension System boosted its holdings in Prestige Consumer Healthcare by 52.2% in the third quarter. Maryland State Retirement & Pension System now owns 10,458 shares of the company’s stock worth $480,000 after purchasing an additional 3,586 shares in the last quarter. Finally, Illinois Municipal Retirement Fund lifted its holdings in Prestige Consumer Healthcare by 7.5% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 25,915 shares of the company’s stock worth $1,189,000 after purchasing an additional 1,797 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.
More Prestige Consumer Healthcare News
Here are the key news stories impacting Prestige Consumer Healthcare this week:
- Positive Sentiment: Fiscal Q2 adjusted earnings were $1.13 per share, topping the $1.07 consensus, while revenue of $336.31 million exceeded estimates of about $329 million and rose 22.7% year over year. Prestige Consumer Healthcare fiscal 2027 second-quarter results
- Neutral Sentiment: Canaccord Genuity lowered its price target from $72 to $70 but maintained a Buy rating. The reduced target is a mild negative, though it still implies substantial upside from the cited share price. Canaccord Genuity Group stock recommendations
- Negative Sentiment: A recent report highlights PBH’s stock drop, but the provided article details do not specify what is driving the decline. The weakness despite an earnings and revenue beat may indicate investors are weighing concerns not explained in the available coverage. Prestige Consumer Healthcare stock dropped: what is driving attention now?
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.
The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.
Featured Stories
- Five stocks we like better than Prestige Consumer Healthcare
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
